The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells

MLA

Laurie A. Ford, et al. “The 4′-O-Benzylated Doxorubicin Analog WP744 Overcomes Resistance Mediated by P-Glycoprotein, Multidrug Resistance Protein and Breast Cancer Resistance Protein in Cell Lines and Acute Myeloid Leukemia Cells.” Investigational New Drugs, vol. 25, Oct. 2006, pp. 115–22. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5f9d7bf2730d1e5f3a92567b20771689&authtype=sso&custid=ns315887.

APA

Laurie A. Ford, Tracy A. Brooks, Hans Minderman, Maria R. Baer, Brian N. Bundy, Michael R. Vredenburg, Ralph J. Bernacki, Waldemar Priebe, & Kieran L. O’Loughlin. (2006). The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Investigational New Drugs, 25, 115–122.

Chicago

Laurie A. Ford, Tracy A. Brooks, Hans Minderman, Maria R. Baer, Brian N. Bundy, Michael R. Vredenburg, Ralph J. Bernacki, Waldemar Priebe, and Kieran L. O’Loughlin. 2006. “The 4′-O-Benzylated Doxorubicin Analog WP744 Overcomes Resistance Mediated by P-Glycoprotein, Multidrug Resistance Protein and Breast Cancer Resistance Protein in Cell Lines and Acute Myeloid Leukemia Cells.” Investigational New Drugs 25 (October): 115–22. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5f9d7bf2730d1e5f3a92567b20771689&authtype=sso&custid=ns315887.